The global population is aging and none of our rheumatic diseases are immune to the impact of the complexities and so-called “geriatric syndromes”, including sarcopenia, frailty, falls and cognitive impairment, associated with the aging process. Whilst we are increasingly aware of these syndromes, it is sometimes overwhelming to consider just how we may incorporate the unique needs of our older patients into our already busy clinical practice –
Over the past 5 years, there has been growing interest in RA-ILD due to its relative prevalence and severity. This seems to be one of the few RA outcomes not improving much, even with the advent of expanded treatment options. There is also a shocking lack of trial data. This year, there were two oral sessions dedicated to RA-ILD, one of which even the overflow room was standing room only, in addition to many posters.
Dr. John Cush RheumNow
1 year 8 months ago
Cyclophosphomide vs Mycophenolate vs Tacrolimus in Lupus Nephritis
Dr. Mike Putman discusses abstract 0670, presented at #ACR24.
https://t.co/aLzsSSOmML https://t.co/XrEtNZAgHI
Dr. John Cush RheumNow
1 year 8 months ago
SELECTing the right patients: upadacitinib in GCA
Dr. Brian Jaros reports on abstract 1695, presented at #ACR24.
https://t.co/x8lLTviOKk https://t.co/yXwwrdgIyu
Dr. John Cush RheumNow
1 year 8 months ago
Assessment of axSpA
Dr. Antoni Chan reviews abstracts 0818 and 0819, presented at #ACR24.
https://t.co/2qI6DnnflP https://t.co/BuTdnlMfxq
Dr. John Cush RheumNow
1 year 8 months ago
PsA Ultrasound Updates
Dr. Catherine Bakewell and Dr. Lihi Eder discuss updates on ultrasound in psoriatic arthritis at #ACR24.
https://t.co/DZBe8uNpJS https://t.co/wIS1hUZnAS
Dr. John Cush RheumNow
1 year 8 months ago
#ACR Best 2024 - Day 4
Although the last day of #ACR24 was but a half day - it was chock full of gems, many coming from the late breaking abstracts presented today. As chosen by the RheumNow faculty, here are some highlight presentations you need to know about.… https://t.co/ws9BOxkZft https://t.co/trMevuvvyX
Dr. John Cush RheumNow
1 year 8 months ago
Methotrexate to Prevent RA, Clear as Mud
Intervention in individuals predisposed to rheumatoid arthritis (RA), aiming for prevention, is a significant topic. Seropositivity for rheumatoid factor and ACPA can precede RA by years. Some patients experience a pre-RA arthralgia… https://t.co/D51CoZAzce https://t.co/lgZalnDeb3
Dr. John Cush RheumNow
1 year 8 months ago
Predicting flares in rheumatic diseases with machine learning
Rheumatic diseases, such as axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA), are marked by unpredictable disease flares that adversely impact quality of life and long-term outcomes.… https://t.co/6oFRp0zyBw https://t.co/fcMrJOg4mM
Dr. John Cush RheumNow
1 year 8 months ago
Changing Mindsets about Methotrexate Side Effects
Dr. Mrinalini Dey discusses abstract 1676, presented at #ACR24.
https://t.co/8RXBWUioee https://t.co/liQ1hN4Xtr
Dr. John Cush RheumNow
1 year 8 months ago
How New Medications are Reframing Imaging Abnormalities in axSpA
Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG
Capillaroscopy is a non-invasive imaging technique used for the in vivo assessment of the microcirculation. kin capillaries at the nailfold are evaluated because the fingers are involved in pathological processes such as Raynaud’s phenomenon. Several abstracts and sessions on nailfold capillaroscopy were presented during ACR24.
In 1950, three scientists were awarded the Nobel Prize for their groundbreaking discovery of steroids, heralded at the time as a "miracle cure" for rheumatoid arthritis (RA). However, just a year after their introduction, evidence began to surface regarding the harmful side effects and withdrawal symptoms such as pain and fatigue that were independent of RA itself.

